Coastal Investment Advisors Inc. lessened its holdings in Eli Lilly And Co (NYSE:LLY) by 8.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,942 shares of the company’s stock after selling 177 shares during the period. Coastal Investment Advisors Inc.’s holdings in Eli Lilly And Co were worth $216,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of the company. Enterprise Trust & Investment Co purchased a new stake in Eli Lilly And Co during the 3rd quarter worth $27,000. Prestige Wealth Management Group LLC purchased a new stake in Eli Lilly And Co during the 2nd quarter worth $34,000. Manchester Financial Inc. purchased a new stake in Eli Lilly And Co during the 2nd quarter worth $40,000. Litman Gregory Asset Management LLC purchased a new stake in Eli Lilly And Co during the 2nd quarter worth $47,000. Finally, Asset Dedication LLC increased its stake in Eli Lilly And Co by 372.9% during the 3rd quarter. Asset Dedication LLC now owns 454 shares of the company’s stock worth $52,000 after buying an additional 358 shares during the period. 76.79% of the stock is currently owned by institutional investors and hedge funds.
Several research firms recently issued reports on LLY. UBS Group dropped their price target on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating on the stock in a research note on Thursday. ValuEngine downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Friday, June 28th. Finally, Bank of America began coverage on shares of Eli Lilly And Co in a research note on Wednesday, October 16th. They set a “buy” rating and a $133.00 price target on the stock. Eight equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Eli Lilly And Co currently has a consensus rating of “Buy” and an average price target of $127.69.
Shares of LLY stock opened at $108.64 on Monday. The firm has a market cap of $104.71 billion, a P/E ratio of 19.57, a P/E/G ratio of 1.85 and a beta of 0.16. The company has a debt-to-equity ratio of 4.98, a current ratio of 1.13 and a quick ratio of 0.87. Eli Lilly And Co has a 1-year low of $104.17 and a 1-year high of $132.13. The firm has a fifty day moving average of $111.18 and a two-hundred day moving average of $114.02.
Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.45 by $0.05. The company had revenue of $5.64 billion during the quarter, compared to analyst estimates of $5.59 billion. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 70.86%. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period last year, the business earned $1.48 EPS. On average, sell-side analysts expect that Eli Lilly And Co will post 5.73 EPS for the current year.
In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of $116.37, for a total transaction of $24,437,700.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Stephen F. Fry sold 9,452 shares of the firm’s stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $115.00, for a total transaction of $1,086,980.00. Following the transaction, the senior vice president now directly owns 100,211 shares of the company’s stock, valued at $11,524,265. The disclosure for this sale can be found here. Over the last three months, insiders have sold 243,452 shares of company stock valued at $28,252,925. 0.11% of the stock is owned by company insiders.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: Understanding the Price to Earnings Ratio (PE)
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.